Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: Implications for tumor suppression

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6064-6074

  Privette, Lisa M ^a   González, Maria E ^a   Ding, Lei ^a   Kleer, Celina G ^a   Petty, Elizabeth M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT WITH FHA AND RING FINGER PROTEIN; ESTROGEN RECEPTOR; SHORT HAIRPIN RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANEUPLOIDY; ARTICLE; BREAST CANCER; BREAST CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS; MITOSIS INDEX; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COLLAGEN; DNA METHYLATION; DRUG COMBINATIONS; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; MITOSIS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PHENOTYPE; PROTEOGLYCANS; RNA, SMALL INTERFERING; TIME FACTORS;

EID: 34447130265     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4109     Document Type: Article

References (41)

1. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000;406:430-5.
2. Summers MK, Bothos J, Halazonetis TD. The CHFR mitotic checkpoint protein delays cell cycle progression by excluding cyclin B1 from the nucleus. Oncogene 2005;24:2589-98.
3. Dang C, Hudis C. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg. Clin Breast Cancer 2006;7:51-8.
4. Sakai M, Hibi K, Kanazumi N, et al. Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma. Hepatogastroenterology 2005;52:1854-7.
5. Satoh A, Toyota M, Itoh F, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003;63:8606-13.
6. Chaturvedi P, Sudakin V, Bobiak ML, et al. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res 2002;62:1797-801.
7. Ogi K, Toyota M, Mita H, et al. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biol Ther 2005;4:773-80.
8. 2 to M transition. J Cell Biol 2002;156:249-59.
9. Matsusaka T, Pines J. Chfr acts with the p38 stress kinases to block entry to mitosis in mammalian cells. J Cell Biol 2004;166:507-16.
10. Shtivelman E. Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR. Mol Cancer Res 2003;1:959-69.
11. Yu X, Minter-Dykhouse K, Malureanu L, et al. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 2005;37:401-6.
12. Brandes JC, van Engeland M, Wouters KA, Weijenberg MP, Herman JG. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 2005;26:1152-6.
13. Cheung HW, Ching YP, Nicholls JM, et al. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Mol Carcinog 2005;43:237-45.
14. Corn PG, Summers MK, Fogt F, et al. Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 2003;24:47-51.
15. Honda T, Tamura G, Waki T, Kawata S, Nishizuka S, Motoyama T. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia. Br J Cancer 2004;90:2013-6.
16. Mariatos G, Bothos J, Zacharatos P, et al. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer. Cancer Res 2003;63:7185-9.
17. Mizuno K, Osada H, Konishi H, et al. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 2002;21:2328-33.
18. Shibata Y, Haruki N, Kuwabara Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 2002;23:1695-9.
19. Tokunaga E, Oki E, Nishida K, et al. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. Breast Cancer Res Treat 2006;97:199-203.
20. Toyota M, Sasaki Y, Satoh A, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A 2003;100:7818-23.
21. Andrieux J, Demory JL, Morel P, et al. Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia. Cancer Genet Cytogenet 2002;137:68-71.
22. Aubele M, Auer G, Braselmann H, et al. Chromosomal imbalances are associated with metastasis-free survival in breast cancer patients. Anal Cell Pathol 2002;24:77-87.
23. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P. Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 2000;28:145-52.
24. Heidenblad M, Schoenmakers EF, Jonson T, et al. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res 2004;64:3052-9.
25. Rutherford S, Hampton GM, Frierson HF, Moskaluk CA. Mapping of candidate tumor suppressor genes on chromosome 12 in adenoid cystic carcinoma. Lab Invest 2005;85:1076-85.
26. Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL. Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res 1993;53:627-35.
27. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
28. Erson AE, Niell BL, DeMers SK, Rouillard JM, Hanash SM, Petty EM. Overexpressed genes/ESTs and characterization of distinct amplicons on 17q23 in breast cancer cells. Neoplasia 2001;3:521-6.
29. Van den Eynden GG, Van der Auwera I, Van Laere S, et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 2004;85:13-22.
30. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11.
31. 2/M checkpoint defects in breast cancer cells. Mol Carcinog 2004;39:26-33.
32. Goto H, Tomono Y, Ajiro K, et al. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem 1999;274:25543-9.
33. Vermes I , Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
34. van Diest PJ, Mouriquand J, Schipper NW, Baak JP. Prognostic value of nucleolar morphometric variables in cytological breast cancer specimens. J Clin Pathol 1990;43:157-9.
35. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-67.
36. Poole C. Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial. Oncology (Huntingt) 2004;18:23-6.
37. Sezgin C, Karabulut B, Uslu R, et al. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. J Chemother 2005;17:96-103.
38. Fraschini R, Bilotta D, Lucchini G, Piatti S. Functional characterization of Dma1 and Dma2, the budding yeast homologues of Schizosaccharomyces pombe Dma1 and human Chfr. Mol Biol Cell 2004;15:3796-810.
39. Guertin DA, Venkatram S, Gould KL, McCollum D. Dma1 prevents mitotic exit and cytokinesis by inhibiting the septation initiation network (SIN). Dev Cell 2002;3:779-90.
40. Band V, Zajchowski D, Kulesa V, Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci U S A 1990;87:463-7.
41. Cowell JK, LaDuca J, Rossi MR, Burkhardt T, Nowak NJ, Matsui S. Molecular characterization of the t(3;9) associated with immortalization in the MCF10A cell line. Cancer Genet Cytogenet 2005;163:23-9.